• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Key factors for non-response to ranibizumab in macular degeneration identified

byChaz Carrier
April 13, 2014
in Chronic Disease, Ophthalmology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Fibrovascular pigment epithelial detachment (PED) and serous PED were associated with non-response to intravitreal ranibizumab treatment as determined by visual acuity testing. 

2. Fibrovascular PED and type 1 choroidal neovascularization were associated with non-response as determined by fundus findings. 

Evidence Rating Level: 2 (Good)            

Study Rundown: For age-related macular degeneration (AMD), intravitreous ranibizumab is an effective treatment option for many patients.  A small subset of patients however, do not respond to this treatment.  In this study, patients with AMD were reviewed to identify and characterize non-responders to intravitreal ranibizumab treatment. The authors found that several factors were associated with non-response to the anti-VEGF treatment as determined by best-corrected visual acuity (BCVA) and fundus findings. These factors include initial fibrovascular pigment epithelial detachment (PED), serous PED, and type 1 choroidal neovascularization. An important strength of this study is a large patient sample size. Limitations in this study include the retrospective study design, which makes it difficult to establish a causal relationship, as well as the large 95% confidence intervals. Nonetheless, this study suggests that ophthalmologists should be aware of these potential predictive factors when treating AMD patients with intravitreal ranibizumab.

Click to read the study in British Journal of Ophthalmology

Relevant Reading: Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes

RELATED REPORTS

Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

Combination of corticosteroid and nonsteroidal anti-inflammatory drug eye drops non-superior to nonsteroidal anti-inflammatory drug monotherapy and sub-Tenon depot for postoperative macular thickening after cataract surgery

In-Depth [retrospective cohort]: This study retrospectively reviewed the clinical records of 141 eyes in 141 AMD patients. All patients received a monthly intravitreal injection of ranibizumab for 3 months followed by PRN intravitreal injections for 9 months. Non-responders to the anti-VEGF treatment were defined as patients with worsened BCVA, increased exudative fundus findings and/or an increased central retinal thickness at 12 months. Logistic regression models were created to analyze non-responders’ initial characteristics. Initial fibrovascular PED (OR=22.9, 95%CI=2.61-201) and serous PED (OR=4.12, 95%CI=1.08-15.8) were associated with non-response to ranibizumab treatment as determined by BCVA. Initial fibrovascular PED (OR=33.5, 95%CI=2.95-381) and type 1 choroidal neovascularization (OR=6.46, 95%CI=1.39-30.0) were associated with non-response as determined by fundus findings.

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: macular degenerationranibizumab
Previous Post

TGF-β1 polymorphism may protect against diabetic retinopathy

Next Post

Childhood sexual abuse associated with later suicide attempts

RelatedReports

Nonpowder gun-related pediatric eye injuries on the rise
Ophthalmology

Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration

June 7, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

March 9, 2022
Statin use linked to increased risk of cataracts
Ophthalmology

Combination of corticosteroid and nonsteroidal anti-inflammatory drug eye drops non-superior to nonsteroidal anti-inflammatory drug monotherapy and sub-Tenon depot for postoperative macular thickening after cataract surgery

August 18, 2021
Health A to Z

Patient Basics: Macular Degeneration

November 30, 2014
Next Post
Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Childhood sexual abuse associated with later suicide attempts

Multiple opioid prescriptions associated with higher hospital admissions

Prenatal SSRI use may increase risk of autism

TV associated with higher BMI in teens

Potential association between toddler behavior and infant media exposure

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options